聞曉光博士，國家級特聘專家，越洋醫(yī)藥創(chuàng)始人、董事長兼CEO。
聞博士是國家衛(wèi)健委新藥創(chuàng)制重大專項的項目負責人，也曾是國家科技部973課題分課題（釋藥技術(shù)及其機理研究）負責人。
聞博士是中國藥學會制劑專業(yè)委員會委員、中國藥學會工業(yè)藥劑學專業(yè)委員會委員、中國顆粒協(xié)會理事、北大醫(yī)學部優(yōu)秀校友。
聞博士回國前曾在葛蘭素史克（GSK）和輝瑞（Pfizer）參與多個緩控釋新藥開發(fā)和上市；回國后曾在藥明康德?lián)沃苿┎繄?zhí)行總監(jiān)，曾擔任科技部制劑新技術(shù)國家重點實驗室主任。
聞博士參與編著《Oral Controlled Release Formulation Design and Drug Delivery：Theory to Practice》(John Wiley & Sons,Inc 出版)一書，以及科技導報關(guān)于緩控釋新藥的特邀綜述《新型制劑的研發(fā)與創(chuàng)新》一文。聞博士擁有15項在中美歐日獲得授權(quán)的緩控釋技術(shù)及產(chǎn)品發(fā)明專利，同時擁有3項實用新型專利。
Dr. Xiaoguang (Gilbert) Wen
Dr. Gilbert Wen is the founder of Overseas Pharmaceuticals Ltd, a specialty pharmaceutical company focusing on developing modified release platform technologies and applying these proprietary technologies to develop NDA products in collaboration with transnational pharmaceutical companies. Among many honors and recognitions, Dr. Wen is a distinguished expert of the Thousand Talent Program (entrepreneurial category) in China and a committee member of Pharmaceutics in Chinese Pharmaceutical Association. In addition, Dr. Wen is a recipient of Distinguished Alumni of Medical School of Beijing University. He holds 15 granted patents and authored a chapter in the book “Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice.”
?
Dr. Wen has previously worked as a formulation scientist in the Product Line Extension division at GSK and in the R&D headquarter for Consumer Health Care Division at Pfizer (Wyeth). After returning to China, he became the head of the State Key Laboratory of Ministry of Science and Technology for Advanced and Novel Controlled Release Technologies and also served as an executive director at Wuxi Apptech.